Regeneron Pharmaceuticals

(NASDAQ) REGN

Current Price$723.11

Market Cap$74.73B

Since IPO (1991)+3,297%

5 Year+42%

1 Year+36%

1 Month-5%

Regeneron Pharmaceuticals Financials at a Glance

Market Cap

$74.73B

Revenue (TTM)

$14.92B

Net Income (TTM)

$4.42B

EPS (TTM)

$41.04

P/E Ratio

17.37

Dividend

$3.58

Beta (Volatility)

0.60 (Low)

Dividend

$3.58

Beta (Volatility)

0.60 (Low)

Price

$723.11

Volume

816,902

Open

$716.39

Price

$723.11

Volume

816,902

Open

$716.39

Previous Close

$723.41

Daily Range

$710.02 - $725.60

52-Week Range

$476.49 - $821.11

Dividend

$3.58

Beta (Volatility)

0.60 (Low)

Price

$723.11

Volume

816,902

Open

$716.39

Previous Close

$723.41

Daily Range

$710.02 - $725.60

52-Week Range

$476.49 - $821.11

REGN News

DNA with a section separated from the main part.

Page 1

REGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regeneron Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

15,410

CEO

Leonard S. Schleifer, MD, PhD

Website

www.regeneron.com

Headquarters

Tarrytown, NY 10591-6707, US

REGN Financials

Key Financial Metrics (TTM)

Gross Margin

85%

Operating Margin

24%

Net Income Margin

30%

Return on Equity

15%

Return on Capital

10%

Return on Assets

11%

Earnings Yield

5.76%

Dividend Yield

0.50%

Payout Ratio

8.46%

Stock Overview

Market Cap

$74.73B

Shares Outstanding

104.84M

Volume

816.90K

Avg. Volume

685.55K

Financials (TTM)

Gross Profit

$12.24B

Operating Income

$3.58B

EBITDA

$5.82B

Operating Cash Flow

$4.98B

Capital Expenditure

$898.40M

Free Cash Flow

$4.08B

Cash & ST Invst.

$8.61B

Total Debt

$2.71B

Regeneron Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$3.61B

+19.0%

Gross Profit

$2.94B

+14.5%

Gross Margin

81.43%

N/A

Market Cap

$74.73B

N/A

Market Cap/Employee

$4.93M

N/A

Employees

15,158

N/A

Net Income

$727.20M

-10.1%

EBITDA

$967.30M

-7.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$6.05B

+7.1%

Accounts Receivable

$5.73B

+3.1%

Inventory

$3.10B

-2.8%

Long Term Debt

$1.99B

-26.6%

Short Term Debt

$720.00M

N/A

Return on Assets

10.82%

N/A

Return on Invested Capital

10.15%

N/A

Free Cash Flow

$848.30M

+9.7%

Operating Cash Flow

$1.08B

+3.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CICigna Corporation

CICigna Corporation$298.49+3.26%

ELVElevance Health Inc.

ELVElevance Health Inc.$393.30+3.03%

CORCencora, Inc.

CORCencora, Inc.$260.93+0.47%

ARGXargenx SE

ARGXargenx SE$812.81-0.06%

IDXXIDEXX Laboratories, Inc.

IDXXIDEXX Laboratories, Inc.$533.92+0.36%

ALNYAlnylam Pharmaceuticals, Inc.

ALNYAlnylam Pharmaceuticals, Inc.$292.03+2.52%

ZTSZoetis Inc.

ZTSZoetis Inc.$76.94+0.35%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$120.61-0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.96-0.05%

NOKNokia

NOKNokia$13.17-0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.96-0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.31+0.03%

WOKWork Medical Technology Group Ltd

WOKWork Medical Technology Group Ltd$6.66+0.70%

SOFISoFi Technologies

SOFISoFi Technologies$15.90-0.02%

Questions About REGN

What is the current price of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals is trading at $723.41 per share.

What is the 52-week range for Regeneron Pharmaceuticals?

Over the past 52 weeks, Regeneron Pharmaceuticals has traded between $476.49 and $821.11.

How much debt does Regeneron Pharmaceuticals have?

As of the most recent reporting period, Regeneron Pharmaceuticals reported total debt of $2.71B.

How much cash does Regeneron Pharmaceuticals have on hand?

Regeneron Pharmaceuticals reported $2.97B in cash and cash equivalents in its most recent financial results.

What is Regeneron Pharmaceuticals’s dividend yield?

Regeneron Pharmaceuticals currently has a dividend yield of 0.50%.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Financials at a Glance

REGN News

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Is This Biotech Stock a Buy After a Groundbreaking Approval?

Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Best Biotech ETFs to Buy in 2026

Best Gene Editing Stocks for 2026 and How to Invest

Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena

Is Regeneron a Multimillionaire-Maker Stock?

REGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Regeneron Pharmaceuticals

REGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Regeneron Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About REGN

What is the current price of Regeneron Pharmaceuticals?

What is the 52-week range for Regeneron Pharmaceuticals?

How much debt does Regeneron Pharmaceuticals have?

How much cash does Regeneron Pharmaceuticals have on hand?

What is Regeneron Pharmaceuticals’s dividend yield?

Premium Investing Services